vs
Cellectis S.A.（CLLS）与Protalix BioTherapeutics, Inc.（PLX）财务数据对比。点击上方公司名可切换其他公司
Cellectis S.A.的季度营收约是Protalix BioTherapeutics, Inc.的1.0倍（$9.5M vs $9.1M），Protalix BioTherapeutics, Inc.净利率更高（-60.3% vs -265.9%，领先205.6%），Cellectis S.A.同比增速更快（375.0% vs -49.9%），Cellectis S.A.自由现金流更多（$27.6M vs $1.6M）
Cellectis S.A.是一家法国生物制药公司，专注于开发用于癌症免疫治疗的基因编辑嵌合抗原受体T细胞技术，目前在巴黎、纽约以及北卡罗来纳州罗利均设有办公机构，在肿瘤免疫基因编辑疗法领域拥有多年研发积累。
Protalix BioTherapeutics是一家以色列制药企业，核心产品为植物源酶制剂他利苷酶阿尔法，该产品已获美国食品药品监督管理局批准，用于治疗戈谢病，专注于开发创新生物技术药物服务患者需求。
CLLS vs PLX — 直观对比
营收规模更大
CLLS
是对方的1.0倍
$9.1M
营收增速更快
CLLS
高出424.9%
-49.9%
净利率更高
PLX
高出205.6%
-265.9%
自由现金流更多
CLLS
多$26.0M
$1.6M
损益表 — Q2 FY2024 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $9.5M | $9.1M |
| 净利润 | $-25.3M | $-5.5M |
| 毛利率 | — | 49.4% |
| 营业利润率 | -181.1% | -51.1% |
| 净利率 | -265.9% | -60.3% |
| 营收同比 | 375.0% | -49.9% |
| 净利润同比 | -51.9% | -184.8% |
| 每股收益（稀释后） | $-0.28 | $-0.06 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CLLSPLX
| Q4 25 | — | $9.1M | ||
| Q3 25 | — | $17.9M | ||
| Q2 25 | — | $15.7M | ||
| Q1 25 | — | $10.1M | ||
| Q4 24 | — | $18.2M | ||
| Q3 24 | — | $18.0M | ||
| Q2 24 | $9.5M | $13.5M | ||
| Q4 23 | — | $10.5M |
净利润CLLSPLX
| Q4 25 | — | $-5.5M | ||
| Q3 25 | — | $2.4M | ||
| Q2 25 | — | $164.0K | ||
| Q1 25 | — | $-3.6M | ||
| Q4 24 | — | $6.5M | ||
| Q3 24 | — | $3.2M | ||
| Q2 24 | $-25.3M | $-2.2M | ||
| Q4 23 | — | $-6.0M |
毛利率CLLSPLX
| Q4 25 | — | 49.4% | ||
| Q3 25 | — | 53.4% | ||
| Q2 25 | — | 62.5% | ||
| Q1 25 | — | 19.1% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | — | 53.4% | ||
| Q2 24 | — | 29.8% | ||
| Q4 23 | — | 15.5% |
营业利润率CLLSPLX
| Q4 25 | — | -51.1% | ||
| Q3 25 | — | 11.9% | ||
| Q2 25 | — | 7.5% | ||
| Q1 25 | — | -41.0% | ||
| Q4 24 | — | 39.6% | ||
| Q3 24 | — | 22.2% | ||
| Q2 24 | -181.1% | -18.0% | ||
| Q4 23 | — | -53.5% |
净利率CLLSPLX
| Q4 25 | — | -60.3% | ||
| Q3 25 | — | 13.2% | ||
| Q2 25 | — | 1.0% | ||
| Q1 25 | — | -35.8% | ||
| Q4 24 | — | 35.6% | ||
| Q3 24 | — | 18.0% | ||
| Q2 24 | -265.9% | -16.4% | ||
| Q4 23 | — | -57.6% |
每股收益（稀释后）CLLSPLX
| Q4 25 | — | $-0.06 | ||
| Q3 25 | — | $0.03 | ||
| Q2 25 | — | $0.00 | ||
| Q1 25 | — | $-0.05 | ||
| Q4 24 | — | $0.10 | ||
| Q3 24 | — | $0.03 | ||
| Q2 24 | $-0.28 | $-0.03 | ||
| Q4 23 | — | $-0.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $149.0M | $14.7M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $148.6M | $48.2M |
| 总资产 | $407.1M | $82.3M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CLLSPLX
| Q4 25 | — | $14.7M | ||
| Q3 25 | — | $13.6M | ||
| Q2 25 | — | $17.9M | ||
| Q1 25 | — | $19.5M | ||
| Q4 24 | — | $19.8M | ||
| Q3 24 | — | $27.4M | ||
| Q2 24 | $149.0M | $23.4M | ||
| Q4 23 | — | $23.6M |
股东权益CLLSPLX
| Q4 25 | — | $48.2M | ||
| Q3 25 | — | $52.9M | ||
| Q2 25 | — | $49.9M | ||
| Q1 25 | — | $45.2M | ||
| Q4 24 | — | $43.2M | ||
| Q3 24 | — | $32.4M | ||
| Q2 24 | $148.6M | $28.6M | ||
| Q4 23 | — | $33.6M |
总资产CLLSPLX
| Q4 25 | — | $82.3M | ||
| Q3 25 | — | $82.3M | ||
| Q2 25 | — | $78.5M | ||
| Q1 25 | — | $73.9M | ||
| Q4 24 | — | $73.4M | ||
| Q3 24 | — | $61.6M | ||
| Q2 24 | $407.1M | $91.5M | ||
| Q4 23 | — | $84.4M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $28.9M | $2.0M |
| 自由现金流经营现金流 - 资本支出 | $27.6M | $1.6M |
| 自由现金流率自由现金流/营收 | 290.5% | 17.8% |
| 资本支出强度资本支出/营收 | 13.2% | 4.4% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-13.6M |
8季度趋势，按日历期对齐
经营现金流CLLSPLX
| Q4 25 | — | $2.0M | ||
| Q3 25 | — | $-3.7M | ||
| Q2 25 | — | $-5.2M | ||
| Q1 25 | — | $-5.1M | ||
| Q4 24 | — | $4.0M | ||
| Q3 24 | — | $4.1M | ||
| Q2 24 | $28.9M | $-3.6M | ||
| Q4 23 | — | $3.6M |
自由现金流CLLSPLX
| Q4 25 | — | $1.6M | ||
| Q3 25 | — | $-4.2M | ||
| Q2 25 | — | $-5.7M | ||
| Q1 25 | — | $-5.4M | ||
| Q4 24 | — | $3.6M | ||
| Q3 24 | — | $4.0M | ||
| Q2 24 | $27.6M | $-3.8M | ||
| Q4 23 | — | $3.3M |
自由现金流率CLLSPLX
| Q4 25 | — | 17.8% | ||
| Q3 25 | — | -23.7% | ||
| Q2 25 | — | -36.2% | ||
| Q1 25 | — | -53.0% | ||
| Q4 24 | — | 19.6% | ||
| Q3 24 | — | 22.4% | ||
| Q2 24 | 290.5% | -28.1% | ||
| Q4 23 | — | 31.9% |
资本支出强度CLLSPLX
| Q4 25 | — | 4.4% | ||
| Q3 25 | — | 2.8% | ||
| Q2 25 | — | 2.8% | ||
| Q1 25 | — | 3.0% | ||
| Q4 24 | — | 2.3% | ||
| Q3 24 | — | 0.5% | ||
| Q2 24 | 13.2% | 1.3% | ||
| Q4 23 | — | 2.4% |
现金转化率CLLSPLX
| Q4 25 | — | — | ||
| Q3 25 | — | -1.58× | ||
| Q2 25 | — | -31.91× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.61× | ||
| Q3 24 | — | 1.27× | ||
| Q2 24 | — | — | ||
| Q4 23 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CLLS
暂无分部数据
PLX
| Products | $8.7M | 95% |
| Other | $428.0K | 5% |
